Bionano Genomics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 10, 2026, disclosing a net loss of $6.453 million for the third quarter and total revenue of $8.276 million.

Key Highlights

  • Q3 2026 net loss: $6.453 million, compared to a net loss of $8.503 million in Q3 2025, according to the filing.
  • Q3 2026 total revenue: $8.276 million, up from $7.367 million in Q3 2025, comprising $7.827 million in product revenue and $449 thousand in service and other revenue.
  • Nine-month net loss: $22.179 million for the nine months ended September 30, 2026, versus $18.462 million for the same period in 2025.
  • Accumulated deficit: $741.799 million as of September 30, 2026, compared to $719.620 million as of December 31, 2025.
  • Total assets: $46.291 million as of September 30, 2026, down from $73.584 million at December 31, 2025.
  • Shares outstanding: 13,989,000 shares of common stock as of November 4, 2026, up from 10,740,200 at December 31, 2025.
  • Cash and cash equivalents: $4.355 million as of September 30, 2026, compared to $2.990 million at December 31, 2025.

Bionano Genomics Reports Q3 2026 Financial Results and Balance Sheet Position

According to the filing, Bionano Genomics (NASDAQ:BNGO) reported total revenue of $8.276 million for the three months ended September 30, 2026, an increase from $7.367 million in the same quarter of 2025. Product revenue accounted for $7.827 million of the Q3 2026 total, while service and other revenue contributed $449 thousand. For the nine months ended September 30, 2026, the company reported total revenue of $23.134 million, up from $20.557 million for the nine months ended September 30, 2025.

The company disclosed a loss from operations of $6.536 million for Q3 2026, compared to $8.538 million in Q3 2025. Operating expenses for the quarter totaled $10.485 million, including $3.042 million in research and development and $7.443 million in selling, general and administrative costs. For the nine-month period, total operating expenses were $33.166 million. The net loss per share, basic and diluted, was $(0.54) for Q3 2026, based on weighted-average common shares outstanding of 11,991,000, compared to $(1.59) per share on 5,338,000 weighted-average shares in Q3 2025.

The condensed consolidated balance sheet as of September 30, 2026, reflected total assets of $46.291 million and total liabilities of $18.081 million, resulting in total stockholders' equity of $28.210 million. The company reported that convertible debentures payable, which carried a fair value of $9.979 million at December 31, 2025, showed a balance of zero as of September 30, 2026. Additional paid-in capital stood at $769.995 million as of September 30, 2026. The company classified itself as a non-accelerated filer and smaller reporting company in the filing.

What Was Disclosed

Bionano Genomics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing a Q3 net loss of $6.453 million, total Q3 revenue of $8.276 million, total assets of $46.291 million, and an accumulated deficit of $741.799 million.